Over the past decade, landmark collaboration between regulatory agencies, pharmaceutical companies, academia, and patient community representatives has enabled the development and approval of new hepatitis C virus (HCV) treatment regimens with unprecedented speed. By providing a neutral platform for cross-sector engagement, the Forum for Collaborative HIV Research's(1) HCV Drug Development Advisory Group played a critical role in fostering this collaboration and expediting drug development. The applicability of this model to other therapeutic areas should be explored.
No takes yet. Share an insight, caveat, or question.
Hutchison et al. (2014) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: